Literature DB >> 9849634

Subchronic toxicity study in mice fed Spirulina maxima.

M Salazar1, E Martínez, E Madrigal, L E Ruiz, G A Chamorro.   

Abstract

The purpose of this study was to evaluate the toxicity of Spirulina maxima, a blue-green alga used as food supplement and food coloring, after 13 weeks of treatment. Groups of ten mice of each sex were given S. maxima in the diet at concentrations of 0 (control), 10, 20 or 30% (w/w) for 13 weeks. The alga ingestion had no effect on behavior, food and water intake, growth or survival. Terminal values in hematology and clinical chemistry did not reveal differences between treated and control groups. However, male and female mice showed significant changes in serum cholesterol levels at 20 and 30% algal concentrations, but a toxic effect of S. maxima was excluded. Post-mortem examination revealed no differences in gross or microscopic findings. Our results show that S. maxima up to high feeding levels did not produce adverse effects in mice after subchronic treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849634     DOI: 10.1016/s0378-8741(98)00080-4

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  13 in total

1.  Analysis of proteome dynamics in the mouse brain.

Authors:  John C Price; Shenheng Guan; Alma Burlingame; Stanley B Prusiner; Sina Ghaemmaghami
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-10       Impact factor: 11.205

Review 2.  Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina.

Authors:  Ruitang Deng; Te-Jin Chow
Journal:  Cardiovasc Ther       Date:  2010-08       Impact factor: 3.023

3.  Brown algae and barley-based anti-obesity food and its safety in C57BL6 mice.

Authors:  Priya Prakash Sharma; V Vanajakshi; Devendra Haware; Vallikannan Baskaran
Journal:  J Food Sci Technol       Date:  2022-06-15       Impact factor: 3.117

Review 4.  Wide Range Applications of Spirulina: From Earth to Space Missions.

Authors:  Giacomo Fais; Alessia Manca; Federico Bolognesi; Massimiliano Borselli; Alessandro Concas; Marco Busutti; Giovanni Broggi; Pierdanilo Sanna; Yandy Marx Castillo-Aleman; René Antonio Rivero-Jiménez; Antonio Alfonso Bencomo-Hernandez; Yendry Ventura-Carmenate; Michela Altea; Antonella Pantaleo; Gilberto Gabrielli; Federico Biglioli; Giacomo Cao; Giuseppe Giannaccare
Journal:  Mar Drugs       Date:  2022-04-28       Impact factor: 6.085

5.  Inhibitory effects of dietary Spirulina platensis on UVB-induced skin inflammatory responses and carcinogenesis.

Authors:  Flandiana Yogianti; Makoto Kunisada; Eiji Nakano; Ryusuke Ono; Kunihiko Sakumi; Sugako Oka; Yusaku Nakabeppu; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-04-14       Impact factor: 8.551

6.  Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial.

Authors:  Mostafa Yakoot; Amel Salem
Journal:  BMC Gastroenterol       Date:  2012-04-12       Impact factor: 3.067

Review 7.  Cyanobacterial lipopolysaccharides and human health - a review.

Authors:  Ian Stewart; Philip J Schluter; Glen R Shaw
Journal:  Environ Health       Date:  2006-03-24       Impact factor: 5.984

8.  Improvement of mercuric chloride-induced testis injuries and sperm quality deteriorations by Spirulina platensis in rats.

Authors:  Gaber E El-Desoky; Samir A Bashandy; Ibrahim M Alhazza; Zeid A Al-Othman; Mourad A M Aboul-Soud; Kareem Yusuf
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

9.  Potential of Spirulina Platensis as a Nutritional Supplement in Malnourished HIV-Infected Adults in Sub-Saharan Africa: A Randomised, Single-Blind Study.

Authors:  M Azabji-Kenfack; S Edie Dikosso; E G Loni; E A Onana; E Sobngwi; E Gbaguidi; A L Ngougni Kana; G Nguefack-Tsague; D Von der Weid; O Njoya; J Ngogang
Journal:  Nutr Metab Insights       Date:  2011-05-02

10.  Spirulina in clinical practice: evidence-based human applications.

Authors:  P D Karkos; S C Leong; C D Karkos; N Sivaji; D A Assimakopoulos
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.